Neuromyelitis Optica- Market Insights, Epidemiology and Market Forecast 2028
SKU ID :MI-13554947 | Published Date: 06-Jun-2019 | No. of pages: 86Description
TOC
Table of Contents
1 Key Insights
2 Neuromyelitis Optica Market Overview at a Glance
2.1 Market Share (%) Distribution of Neuromyelitis Optica in 2018
2.2 Market Share (%) Distribution of Neuromyelitis Optica in 2028
3 Neuromyelitis Optica: Disease Background and Overview
3.1 Introduction
3.2 Symptoms
3.3 Etiology
3.4 Risk Factor
3.5 Pathophysiology
3.6 Diagnosis
3.7 Treatment
4 Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Neuromyelitis Optica in 7MM
4.3. Total Prevalent Patient Population of Neuromyelitis Optica in 7MM – By Countries
5 Epidemiology of Neuromyelitis Optica by Countries (2016-2028)
5.1 United States- Epidemiology (2016-2028)
5.1.1 Assumptions and Rationale
5.1.2 Prevalent/Incident Cases of Neuromyelitis Optica in the United States
5.1.3 Sub-Type Specific cases of Neuromyelitis Optica in the United States
5.1.4 Sex- Specific Cases of Neuromyelitis Optica in the United States
5.1.5 Diagnosed Cases of Neuromyelitis Optica in the United States
5.1.6 Treatable Cases of Neuromyelitis Optica in the United States
5.2 EU5 Countries
5.2.1 Germany
5.2.1.1 Assumptions and Rationale
5.2.1.2 Prevalent/Incident Cases of the of Neuromyelitis Optica in the Germany
5.2.1.3 Sub-Type Specific cases of Neuromyelitis Optica in the Germany
5.2.1.4 Sex- Specific Cases of the Neuromyelitis Optica in the Germany
5.2.1.5 Diagnosed Cases of the Neuromyelitis Optica in the Germany
5.2.1.6 Treatable Cases of the Neuromyelitis Optica
5.2.2 France
5.2.2.1 Assumptions and Rationale
5.2.2.2 Prevalent/Incident Cases of the of Neuromyelitis Optica in the France
5.2.2.3 Sub-Type Specific cases of Neuromyelitis Optica in the France
5.2.2.4 Sex- Specific Cases of the Neuromyelitis Optica in the France
5.2.2.5 Diagnosed Cases of the Neuromyelitis Optica in the France
5.2.2.6 Treatable Cases of the Neuromyelitis Optica
5.2.3 Italy
5.2.3.1 Assumptions and Rationale
5.2.3.2 Prevalent/Incident Cases of the of Neuromyelitis Optica in the Italy
5.2.3.3 Sub-Type Specific cases of Neuromyelitis Optica in the Italy
5.2.3.4 Sex- Specific Cases of the Neuromyelitis Optica in the Italy
5.2.3.5 Diagnosed Cases of the Neuromyelitis Optica in the Italy
5.2.3.6 Treatable Cases of the Neuromyelitis Optica
5.2.4 Spain
5.2.4.1 Assumptions and Rationale
5.2.4.2 Prevalent/Incident Cases of the of Neuromyelitis Optica in the Spain
5.2.4.3 Sub-Type Specific cases of Neuromyelitis Optica in the Spain
5.2.4.4 Sex- Specific Cases of the Neuromyelitis Optica in the Spain
5.2.4.5 Diagnosed Cases of the Neuromyelitis Optica in the Spain
5.2.4.6 Treatable Cases of the Neuromyelitis Optica
5.2.5 United Kingdom
5.2.5.1 Assumptions and Rationale
5.2.5.2 Prevalent/Incident Cases of the of Neuromyelitis Optica in the United Kingdom
5.2.5.3 Sub-Type Specific cases of Neuromyelitis Optica in the United Kingdom
5.2.5.4 Sex- Specific Cases of the Neuromyelitis Optica in the United Kingdom
5.2.5.5 Diagnosed Cases of the Neuromyelitis Optica in the United Kingdom
5.2.5.6 Treatable Cases of the Neuromyelitis Optica
5.3 Japan
5.3.1 Assumptions and Rationale
5.3.2 Prevalent/Incident Cases of the of Neuromyelitis Optica in the Japan
5.3.3 Sub-Type Specific cases of Neuromyelitis Optica in the Japan
5.3.4 Sex- Specific Cases of the Neuromyelitis Optica in the Japan
5.3.5 Diagnosed Cases of the Neuromyelitis Optica in the Japan
5.3.6 Treatable Cases of the Neuromyelitis Optica
6 Current Treatment & Medical practices
6.1 Treatment Algorithm
6.2 Treatment Guidelines
7 Unmet Needs
8 Marketed Product
8.1 Drug A: Company 1
8.1.1 Drug Description
8.1.2 Mechanism of Action
8.1.3 Clinical Trials Details
8.1.4 Advantages & Disadvantages
8.1.5 Safety and Efficacy
8.1.6 Product Profile
8.2 Drug B: Company 2
8.2.1 Drug Description
8.2.2 Mechanism of Action
8.2.3 Clinical Trials Details
8.2.4 Advantages & Disadvantages
8.2.5 Safety and Efficacy
8.2.6 Product Profile
8.3 Drug C: Company 3
8.3.1 Drug Description
8.3.2 Mechanism of Action
8.3.3 Clinical Trials Details
8.3.4 Advantages & Disadvantages
8.3.5 Safety and Efficacy
8.3.6 Product Profile
8.4 Drug D: Company 4
8.4.1 Drug Description
8.4.2 Mechanism of Action
8.4.3 Clinical Trials Details
8.4.4 Advantages & Disadvantages
8.4.5 Safety and Efficacy
8.4.6 Product Profile
8.5 Drug E: Company 5
8.5.1 Drug Description
8.5.2 Mechanism of Action
8.5.3 Clinical Trials Details
8.5.4 Advantages & Disadvantages
8.5.5 Safety and Efficacy
8.5.6 Product Profile
8.6 : Company 6
8.6.1 Drug Description
8.6.2 Mechanism of Action
8.6.3 Clinical Trials Details
8.6.4 Advantages & Disadvantages
8.6.5 Safety and Efficacy
8.6.6 Product Profile
8.7 : Company 7
8.7.1 Drug Description
8.7.2 Mechanism of Action
8.7.3 Clinical Trials Details
8.7.4 Advantages & Disadvantages
8.7.5 Safety and Efficacy
8.7.6 Product Profile
8.8 : Company 8
8.8.1 Drug Description
8.8.2 Mechanism of Action
8.8.3 Clinical Trials Details
8.8.4 Advantages & Disadvantages
8.8.5 Safety and Efficacy
8.8.6 Product Profile
9 Emerging Drugs
9.1 Key Cross Competition
9.2 Emerging company
9.2.1 Emerging Drug A: Company 14
9.2.1.1 Other Development Activities
9.2.1.2 Clinical Development
9.2.1.3 Clinical Trials Information
9.2.1.4 Safety and Efficacy
9.2.1.5 Advantages and Disadvantages
9.2.1.6 Product Profile
9.2.2 Emerging Drug B: Company 15
9.2.2.1 Other Development Activities
9.2.2.2 Clinical Development
9.2.2.3 Clinical Trials Information
9.2.2.4 Safety and Efficacy
9.2.2.5 Advantages and Disadvantages
9.2.2.6 Product Profile
9.2.3 Emerging Drug C: Company 16
9.2.3.1 Other Development Activities
9.2.3.2 Clinical Development
9.2.3.3 Clinical Trials Information
9.2.3.4 Safety and Efficacy
9.2.3.5 Advantages and Disadvantages
9.2.3.6 Product Profile
9.2.4 Emerging Drug D: Company 17
9.2.4.1 Other Development Activities
9.2.4.2 Clinical Development
9.2.4.3 Clinical Trials Information
9.2.4.4 Safety and Efficacy
9.2.4.5 Advantages and Disadvantages
9.2.4.6 Product Profile
9.2.5 Emerging Drug E: Company 18
9.2.5.1 Other Development Activities
9.2.5.2 Clinical Development
9.2.5.3 Clinical Trials Information
9.2.5.4 Safety and Efficacy
9.2.5.5 Advantages and Disadvantages
9.2.5.6 Product Profile
10 7MM Market Analysis
10.1 7MM Market Size of Neuromyelitis Optica
10.2 7MM Percentage Share of Drugs Marketed for Neuromyelitis Optica
10.3 7MM Market Sales of Neuromyelitis Optica by Products
11 The United States Market Outlook
11.1 Market Size of Neuromyelitis Optica in United States
11.2 Percentage Share of Drugs Marketed for Neuromyelitis Optica in United States
11.3 Market Sales of Neuromyelitis Optica by Products in United States
11.4 Analysis of Upcoming Therapies and Impact on the Market
12 EU5 Countries Market Outlook
12.1 Market Size of Neuromyelitis Optica in EU5
12.2 Market Size of Neuromyelitis Optica in Germany
12.2.1 Market Size of Neuromyelitis Optica in Germany
12.2.2 Percentage Share of Drugs Marketed for Neuromyelitis Optica in Germany
12.2.3 Market Sales of Neuromyelitis Optica by Products in Germany
12.2.4 Analysis of Upcoming Therapies and Impact on the Market
12.3 Market Size of Neuromyelitis Optica in France
12.3.1 Market Size of Neuromyelitis Optica in France
12.3.2 Percentage Share of Drugs Marketed for Neuromyelitis Optica in France
12.3.3 Market Sales of Neuromyelitis Optica by Products in France
12.3.4 Analysis of Upcoming Therapies and Impact on the Market
12.4 Market Size of Neuromyelitis Optica in Italy
12.4.1 Market Size of Neuromyelitis Optica in Italy
12.4.2 Percentage Share of Drugs Marketed for Neuromyelitis Optica in Italy
12.4.3 Market Sales of Neuromyelitis Optica by Products in Italy
12.4.4 Analysis of Upcoming Therapies and Impact on the Market
12.5 Market Size of Neuromyelitis Optica in Spain
12.5.1 Market Size of Neuromyelitis Optica in Spain
12.5.2 Percentage Share of Drugs Marketed for Neuromyelitis Optica in Spain
12.5.3 Market Sales of Neuromyelitis Optica by Products in Spain
12.5.4 Analysis of Upcoming Therapies and Impact on the Market
12.6 Market Size of Neuromyelitis Optica in United Kingdom
12.6.1 Market Size of Neuromyelitis Optica in United Kingdom
12.6.2 Percentage Share of Drugs Marketed for Neuromyelitis Optica in United Kingdom
12.6.3 Market Sales of Neuromyelitis Optica by Products in United Kingdom
12.6.4 Analysis of Upcoming Therapies and Impact on the Market
13 The Japan Market Outlook
13.1 Market Size of Neuromyelitis Optica in Japan
13.2 Percentage Share of Drugs Marketed for Neuromyelitis Optica in Japan
13.3 Market Sales of Neuromyelitis Optica by Products in Japan
13.4 Analysis of Upcoming Therapies and Impact on the Market
14 Cost Analysis of Neuromyelitis Optica
15 Generic Competition in Neuromyelitis Optica Market
16 Market Drivers
17 Market Barriers
18 Report Methodology
18.1 Methodology/Research Approach
18.2 Data Source
18.2.1 Secondary Sources
18.2.2 Primary Sources
Tables & Figures
List of Tables
Table Total Prevalent/Incident Cases of the Neuromyelitis Optica in 7MM (2016-2028)
Table Total Prevalent/Incident Cases of the Neuromyelitis Optica in 7MM by Countries (2016-2028)
Table Prevalent/Incident Cases of the Neuromyelitis Optica in United States (2016-2028)
Table Sub-Type Specific cases of Neuromyelitis Optica in the United States (2016-2028)
Table Sex- Specific Cases of Neuromyelitis Optica in the United States (2016-2028)
Table Diagnosed Cases of the Neuromyelitis Optica in United States (2016-2028)
Table Treatable Cases of the Neuromyelitis Optica in United States (2016-2028)
Table Prevalent/Incident Cases of the Neuromyelitis Optica in Germany (2016-2028)
Table Sub-Type Specific cases of Neuromyelitis Optica in the Germany (2016-2028)
Table Sex- Specific Cases of Neuromyelitis Optica in the Germany (2016-2028)
Table Diagnosed Cases of the Neuromyelitis Optica in Germany (2016-2028)
Table Treatable Cases of the Neuromyelitis Optica in Germany (2016-2028)
Table Prevalent/Incident Cases of the Neuromyelitis Optica in France (2016-2028)
Table Sub-Type Specific cases of Neuromyelitis Optica in the France (2016-2028)
Table Sex- Specific Cases of Neuromyelitis Optica in the France (2016-2028)
Table Diagnosed Cases of the Neuromyelitis Optica in France (2016-2028)
Table Treatable Cases of the Neuromyelitis Optica in France (2016-2028)
Table Prevalent/Incident Cases of the Neuromyelitis Optica in Italy (2016-2028)
Table Sub-Type Specific cases of Neuromyelitis Optica in the Italy (2016-2028)
Table Sex- Specific Cases of Neuromyelitis Optica in the Italy (2016-2028)
Table Diagnosed Cases of the Neuromyelitis Optica in Italy (2016-2028)
Table Treatable Cases of the Neuromyelitis Optica in Italy (2016-2028)
Table Prevalent/Incident Cases of the Neuromyelitis Optica in Spain (2016-2028)
Table Sub-Type Specific cases of Neuromyelitis Optica in the Spain (2016-2028)
Table Sex- Specific Cases of Neuromyelitis Optica in the Spain (2016-2028)
Table Diagnosed Cases of the Neuromyelitis Optica in Spain (2016-2028)
Table Treatable Cases of the Neuromyelitis Optica in Spain (2016-2028)
Table Prevalent/Incident Cases of the Neuromyelitis Optica in United Kingdom (2016-2028)
Table Sub-Type Specific cases of Neuromyelitis Optica in the United Kingdom (2016-2028)
Table Sex- Specific Cases of Neuromyelitis Optica in the United Kingdom (2016-2028)
Table Diagnosed Cases of the Neuromyelitis Optica in United Kingdom (2016-2028)
Table Treatable Cases of the Neuromyelitis Optica in United Kingdom (2016-2028)
Table Prevalent/Incident Cases of the Neuromyelitis Optica in Japan (2016-2028)
Table Sub-Type Specific cases of Neuromyelitis Optica in the Japan (2016-2028)
Table Sex- Specific Cases of Neuromyelitis Optica in the Japan (2016-2028)
Table Diagnosed Cases of the Neuromyelitis Optica in Japan (2016-2028)
Table Treatable Cases of the Neuromyelitis Optica in Japan (2016-2028)
Table Drug Description
Table Mechanism of Action
Table Clinical Trials Details
Table Advantages & Disadvantages
Table Safety and Efficacy
Table Product Profile
Table Drug Description
Table Mechanism of Action
Table Clinical Trials Details
Table Advantages & Disadvantages
Table Safety and Efficacy
Table Product Profile
Table Drug Description
Table Mechanism of Action
Table Clinical Trials Details
Table Advantages & Disadvantages
Table Safety and Efficacy
Table Product Profile
Table Drug Description
Table Mechanism of Action
Table Clinical Trials Details
Table Advantages & Disadvantages
Table Safety and Efficacy
Table Product Profile
Table Drug Description
Table Mechanism of Action
Table Clinical Trials Details
Table Advantages & Disadvantages
Table Safety and Efficacy
Table Product Profile
Table Drug Description
Table Mechanism of Action
Table Clinical Trials Details
Table Advantages & Disadvantages
Table Safety and Efficacy
Table Product Profile
Table Drug Description
Table Mechanism of Action
Table Clinical Trials Details
Table Advantages & Disadvantages
Table Safety and Efficacy
Table Product Profile
Table Drug Description
Table Mechanism of Action
Table Clinical Trials Details
Table Advantages & Disadvantages
Table Safety and Efficacy
Table Product Profile
Table Comparison of emerging drugs (Immunomodulators) under development
Table Comparison of emerging drugs (other classes) under development
Table Safety and Efficacy
Table Product Advantages and Advantages
Table Clinical Trial Description, 2018
Table Safety and Efficacy
Table Product Advantages and Advantages
Table Clinical Trial Description, 2018
Table Safety and Efficacy
Table Product Advantages and Advantages
Table Clinical Trial Description, 2018
Table Safety and Efficacy
Table Product Advantages and Advantages
Table Clinical Trial Description, 2018
Table Safety and Efficacy
Table Product Advantages and Advantages
Table Clinical Trial Description, 2018
Table7MM- Market Size of Neuromyelitis Optica in USD MM (2016-2028)
Table 7MM- Market Share Neuromyelitis Optica by Therapies in USD MM (2016-2028)
Table 7MM- Market Sales of Neuromyelitis Optica by Therapies in USD MM (2016-2028)
Table US Market Size of Neuromyelitis Optica in USD, Million (2016-2028)
Table United States-Market Share Neuromyelitis Optica by Therapies in USD MM (2016-2028)
Table United States-Market Sales of Neuromyelitis Optica by Therapies in USD MM (2016-2028)
Table EU5 Market Size of Neuromyelitis Optica (MS) in USD, Million (2016-2028)
Table Germany Market Size of Neuromyelitis Optica in USD, Million (2016-2028)
Table Germany -Market Share Neuromyelitis Optica by Therapies in USD MM (2016-2028)
Table Germany -Market Sales of Neuromyelitis Optica by Therapies in USD MM (2016-2028)
Table France Market Size of Neuromyelitis Optica in USD, Million (2016-2028)
Table France -Market Share Neuromyelitis Optica by Therapies in USD MM (2016-2028)
Table France -Market Sales of Neuromyelitis Optica by Therapies in USD MM (2016-2028)
Table Italy Market Size of Neuromyelitis Optica in USD, Million (2016-2028)
Table Italy -Market Share Neuromyelitis Optica by Therapies in USD MM (2016-2028)
Table Italy -Market Sales of Neuromyelitis Optica by Therapies in USD MM (2016-2028)
Table Spain Market Size of Neuromyelitis Optica in USD, Million (2016-2028)
Table Spain -Market Share Neuromyelitis Optica by Therapies in USD MM (2016-2028)
Table Spain -Market Sales of Neuromyelitis Optica by Therapies in USD MM (2016-2028)
Table United Kingdom Market Size of Neuromyelitis Optica in USD, Million (2016-2028)
Table United Kingdom -Market Share Neuromyelitis Optica by Therapies in USD MM (2016-2028)
Table United Kingdom -Market Sales of Neuromyelitis Optica by Therapies in USD MM (2016-2028)
Table Japan Market Size of Neuromyelitis Optica in USD, Million (2016-2028)
Table Japan -Market Share Neuromyelitis Optica by Therapies in USD MM (2016-2028)
Table Japan -Market Sales of Neuromyelitis Optica by Therapies in USD MM (2016-2028)
Table Market Drivers of Neuromyelitis Optica
Table Market Barriers of Neuromyelitis Optica
???
Companies
- PRICE
-
$5980$12980